Search Result
Results for "
Payload
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-128952
-
|
SG3249
|
Drug-Linker Conjugates for ADC
DNA Alkylator/Crosslinker
|
Cancer
|
|
Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
|
-
-
- HY-101161
-
SG3199
3 Publications Verification
|
DNA Alkylator/Crosslinker
ADC Payload
|
Cancer
|
|
SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249) .
|
-
-
- HY-132162
-
|
|
ADC Payload
|
Cancer
|
|
7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .
|
-
-
- HY-101127
-
|
PBD dimer
|
ADC Payload
|
Cancer
|
|
SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.
|
-
-
- HY-147193
-
|
|
NAMPT
|
Cancer
|
|
Nampt-IN-10 TFA (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 TFA shows cellular potency to A2780 and CORL23 cells lines with IC50s of 5 and 19 nM, respectively. Nampt-IN-10 TFA can be used as a novel non-antimitotic payload for ADCs .
|
-
-
- HY-101141
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
|
-
-
- HY-P10736A
-
|
|
GCGR
|
Metabolic Disease
|
|
AMG133 peptide payload TFA is a GLP-1 analog agonist peptide. AMG133 peptide payload TFA potently activates GLP-1R and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload TFA can be used for the synthesis of AMG 133 (HY-164535) .
|
-
-
- HY-P10736
-
|
|
GCGR
|
Metabolic Disease
|
|
AMG133 peptide payload is a GLP-1 analog agonist peptide. AMG133 peptide potently activates GLP-1R, and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload can be used for the synthesis of AMG 133 (HY-164535) .
|
-
-
- HY-117371
-
|
(-)-Hemiasterlin; Milnamide B
|
ADC Payload
|
Cancer
|
|
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effects. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .
|
-
-
- HY-126663
-
|
|
ADC Payload
|
Cancer
|
|
N-Me-L-Ala-maytansinol is a hydrophobic, cell permeable payload used for making antibody-drug conjugate (ADC) .
|
-
-
- HY-147363
-
|
|
Drug-Linker Conjugates for ADC
|
Others
|
|
DIBAC-GGFG-NH2CH2-Dxd (compound LP4), a Camptothecin (HY-16560) derivative, is a linker-payload of protein-agent conjugates . Dxd (HY-13631D) can be used as a payload for the antibody-coupling drug ADC (DS-8201a).DIBAC-GGFG-NH2CH2-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .
|
-
-
- HY-46759
-
|
|
Liposome
|
Infection
|
|
Genevant CL1 is an ionizable lipid (pKa = 6.3) suitable for the preparation of lipid nanoparticles (LNPs) for delivering nucleic acid payloads and intramuscular vaccines. Genevant CL1 is a component of lipid nanoparticle delivery systems for mRNA vaccines .
|
-
-
- HY-141600
-
|
BAY 1187982
|
Antibody-Drug Conjugates (ADCs)
FGFR
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .
|
-
-
- HY-175203
-
-
-
- HY-139441
-
-
-
- HY-12460
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.
|
-
-
- HY-148127
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470 (HY-148128), with antitumor activity .
|
-
-
- HY-132158
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonal antibody (mAb) for the synthesis of camptothecin antibody-drug conjugate (ADC) .
|
-
-
- HY-15581
-
|
Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10
|
Microtubule/Tubulin
ADC Payload
|
Cancer
|
|
MMAD is a potent tubulin inhibitor, is a toxin payload in antibody agent conjugates (ADCs).
|
-
-
- HY-147408
-
|
SHR9265
|
Topoisomerase
ADC Payload
|
Cancer
|
|
Rezetecan (SHR9265) is a topoisomerase I inhibitor. In addition, Rezetecan can be used to synthesize Trastuzumab rezetecan, an antineoplastic agent. Rezetecán can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .
|
-
-
- HY-154915
-
-
-
- HY-176844
-
|
|
ADC Payload
Drug Intermediate
|
Cancer
|
|
eIF4A-IN-1 intermediate (Compound 71E) is an intermediate of Eukaryotic translation initiation factor 4A (eIF4A) inhibitor. eIF4A-IN-1 intermediate can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-156756
-
|
|
ADC Payload
|
Cancer
|
|
7-Hydroxymethyl-10,11-MDCPT is a hydrophilic camptothecin analog. 7-Hydroxymethyl-10,11-MDCPT is a payload that can be used for ADC synthesis .
|
-
-
- HY-177585
-
|
BLD1102
|
ADC Payload
Topoisomerase
|
Cancer
|
|
BCPT02 (BLD1102) is a Topoisomerase-I inhibitor and ADC payload (ADC Payload). BCPT02 can form the ADC BCG041. BCPT02 is applicable to cancer-related research .
|
-
-
- HY-148128
-
|
|
Microtubule/Tubulin
ADC Payload
|
Cancer
|
|
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .
|
-
-
- HY-176976
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Exatecan-mpGNNG (Compound 10a) is the linker-payload component of an antibody-drug conjugate (ADC). Exatecan-mpGNNG is composed of Exatecan (HY-13631), a potent topoisomerase I inhibitor, and the linker .
|
-
-
- HY-107502
-
|
|
ADC Payload
|
Cancer
|
|
Cryptophycin analog 1 is an ADC payload. Cryptophycin analog 1 shows anticancer activity. Cryptophycin analog 1 displays cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1 .
|
-
-
- HY-132162A
-
|
|
ADC Payload
|
Cancer
|
|
7-MAD-MDCPT hydrochloride, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .
|
-
-
- HY-159854
-
|
|
Liposome
|
Cancer
|
|
C14-O2 is an ionizable cationic lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
-
- HY-145078
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5 .
|
-
-
- HY-W190913
-
|
|
ADC Linker
|
Cancer
|
|
DBCO-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. PNP can be substituted by amine-containing payload. DBCO enable click chemistry with azide molecules.
|
-
-
- HY-177285
-
|
|
Kinesin
ADC Payload
|
Cancer
|
|
NVP-BQS481 (Compound 1) is a selective Kinesin spindle protein-5 (Eg5) inhibitor with an IC50< 0.5 nM. NVP-BQS481 has significant antimitotic and antitumor activity (IC50: 0.0.9 nM for SK-OV-3ip cells). NVP-BQS481 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-176202
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC (compound LIV1-IMC (12) linker-payload) is a linker-payload conjugate, used in the synthesis of antibody-drug conjugates (ADCs).TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC contains TLR7/8 agonist (HY-170770) (ADC payload) and a linker (HY-176478) .
|
-
-
- HY-164429
-
|
|
Integrin
Elastase
|
Cancer
|
|
VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .
|
-
-
- HY-102001
-
|
|
ADC Payload
|
Cancer
|
|
Tomaymycin DM is a tomaymycin derivative, PBD monomer, and DNA alkylating agent. Tomaymycin DM can serve as a payload in tumor-targeting antibody-conjugated active molecules (ADCs).
|
-
-
- HY-171269
-
|
|
ADC Antibody
Mesothelin
|
Cancer
|
|
Anetumab-MMAE is an antibody-drug conjugate (ADC) (Anetumab antibody (HY-P99352), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is an anti-mesothelin (MSLN) antibody.
|
-
-
- HY-171270
-
|
|
Antibody-Drug Conjugates (ADCs)
Mucin
|
Cancer
|
|
Clivatuzumab-MMAE is an antibody-drug conjugate (ADC) (Clivatuzumab antibody (HY-P99968), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is a humanized anti-mucin monoclonal antibody.
|
-
-
- HY-156756S
-
-
-
- HY-156249
-
|
|
ADC Payload
|
Cancer
|
|
NMS-P528 is a Duocarmycin derivative that can be used as an ADC payload. NMS-P528 can be used to synthesize NMS-P945 .
|
-
-
- HY-171081
-
|
|
ADC Payload
Glucocorticoid Receptor
|
Cancer
|
|
Glucocorticoid receptor agonist-6 (Compound A) is a Glucocorticoid receptor (GR) agonist. Glucocorticoid receptor agonist-6 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-135901
-
|
|
ADC Payload
Bacterial
|
Cancer
|
|
Py-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Py-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .
|
-
-
- HY-176843
-
-
-
- HY-178270
-
|
|
ADC Payload
|
Inflammation/Immunology
Cancer
|
|
PBD derivative-1 (Compound 7-8) is a derivative of PBD, and PBD is the payload in antibody-drug conjugates (ADCs). PBD derivative-1 can be used for the synthesis of ADCs.
|
-
-
- HY-164107
-
|
|
ADC Payload
Microtubule/Tubulin
|
Cancer
|
|
Auristatin S is an Auristatin payload with potent antitumor activity. Auristatin S attenuates bystander activity with improved off-target toxicity. Auristatin S has excellent tolerability in Karpas/KarpasBVR cell models. Auristatin S can be used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types .
|
-
-
- HY-135900
-
|
|
ADC Payload
Bacterial
|
Cancer
|
|
Aniline-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Aniline-MPB-amino-C3-PBD is a sequence-selective DNA minor-groove binding agent. Aniline-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .
|
-
-
- HY-175004
-
|
|
ADC Payload
DNA Alkylator/Crosslinker
|
Cancer
|
|
PBD dimer-4 (Compound 7) is a C1-subsitituted PBD dimer. PBD dimer-4 has high DNA-binding affinity, DNA cross-linking ability and potent cytotoxicity against MDA-MB-231 cells (IC50: 236 nM). PBD dimer-4 can be used as a payload of ADC Loncastuximab tesirine (HY-P99349) to treat several different cancer types .
|
-
-
- HY-W1117786
-
|
|
ADC Payload
NAMPT
|
Cancer
|
|
Nampt-IN-10 (Compound 4) is an efficient inhibitor of nicotinamide phosphoribosyltransferase (NAMPT). Nampt-IN-10 exhibits nanomolar-level inhibitory activity against cell lines such as MDA-MB453, NCI-N87, and NCI-H526. Nampt-IN-10 can be used as an ADC payload, and the ADC constructed with it as the core demonstrates significant anti-tumor activity .
|
-
-
- HY-159865
-
|
|
Liposome
|
Others
|
|
CL15F6 is an ionizable lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
-
- HY-159856
-
|
Diphosphatidylglycerol (16:0)
|
Liposome
|
Others
|
|
16:0 Cardiolipin (Diphosphatidylglycerol (16:0)) is a phospholipid derived from Palmitic acid (16:0) that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
-
- HY-13631K
-
|
|
ADC Payload
|
Cancer
|
|
(1R,9S)-Dxd is an isomer of (Dxd) HY-13631D. (1R,9S)-Dxd is an ADC payload that can be used in the synthesis of ADCs (antibody-drug conjugates) .
|
-
- HY-160597
-
|
|
ADC Payload
Topoisomerase
|
Cancer
|
|
Exatecan-amide-bicyclo[1.1.1]pentan-1-ol (Compound 79) is an exatecan (HY-13631) derivative that can be used as a payload in drug conjugates. Exatecan-amide-bicyclo[1.1.1]pentan-1-ol has significant inhibitory activity against a variety of tumor cell lines .
|
-
![Exatecan-amide-bicyclo[1.1.1]pentan-1-ol](//file.medchemexpress.com/product_pic/hy-160597.gif)
- HY-176777
-
|
|
Drug Derivative
ADC Payload
|
Cancer
|
|
7-Methylol-9-methoxy-10-F-camptothecin (Compound D6-1) is a derivative of Camptothecin (HY-16560). 7-Methylol-9-methoxy-10-F-camptothecin can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-132162B
-
|
|
ADC Payload
|
Cancer
|
|
7-MAD-MDCPT TFA, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .
|
-
- HY-164705
-
-
- HY-159862
-
|
|
Liposome
|
Infection
|
|
IM21.7c is a cationic lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
- HY-164730
-
|
ADCT-602; hLL2-Cys-PBD
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted ADC. Epratuzumab Tesirine contains a PBD dimer and a payload SG3249 .
|
-
- HY-169324
-
|
Mal-Exo-EEVC-Exatecan
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
APL-1092 (Mal-Exo-EEVC-Exatecan) is a drug-linker conjugate for ADC, which contains Exatecan (HY-13631) (ADC payload) and a linker .
|
-
- HY-W591449
-
|
|
Liposome
|
Cancer
|
|
DOPE-PEG2000-Azide is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .
|
-
- HY-171159
-
-
- HY-157078
-
|
|
ADC Payload
|
Cancer
|
|
Eg5-IN-2 (Compound Scaffold B (4)) is an Eg5 inhibitor (IC50: < 0.5 nM). Eg5-IN-2 can be used as an ADC payload for synthesis of ADCs .
|
-
- HY-46759A
-
|
|
Liposome
|
Infection
|
|
Genevant CL1 monohydrochloride is an ionizable lipid (pKa = 6.3) suitable for the preparation of lipid nanoparticles (LNPs) for delivering nucleic acid payloads and intramuscular vaccines. Genevant CL1 monohydrochloride is a component of lipid nanoparticle delivery systems for mRNA vaccines .
|
-
- HY-186048
-
|
|
Drug-Linker Conjugates for ADC
|
Infection
|
|
MC-VC-PAB-Daptomycin (Compound 54) is the linker-payload of an antibody-drug conjugate (ADC). β-Glucuronide-dPBD-PEG6-NH2 is composed of Daptomycin (HY-13631), a lipopeptide antibiotic, and the linker .
|
-
- HY-164787
-
-
- HY-174283
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Tri-valent linker-3 is a linker targeting Polymyxin B (PMB) and can be used to synthesize PMB-based drug delivery systems. Polymyxin B carries molecular payloads (e.g., nucleic acid agents) through the linker and binds megalin (a cell surface factor on the surface of target cells) with high affinity, thereby delivering the payload to tissues or cells .
|
-
- HY-160512
-
|
|
Liposome
|
Others
|
Lipid 9 is an ionizable lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
- HY-163672
-
|
|
Glucocorticoid Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
Glucocorticoid receptor modulator 3 (Payload 6) is a thioester-containing glucocorticoid receptor modulator (IC50=0.6 nM). Glucocorticoid receptor modulator 3 is designed to inactivate unconjugated payloads rapidly through liver metabolism, thereby minimizing systemic exposure. Glucocorticoid receptor modulator 3 can be utilized in the development of antibody-drug conjugates (ADCs) targeting autoimmune diseases .
|
-
- HY-164707
-
-
- HY-159853
-
|
|
Liposome
|
Inflammation/Immunology
|
|
C14-A1 is an ionizable cationic lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
- HY-159855
-
|
Cholesterol-amino-phosphate 2 hydrochloride
|
Liposome
|
Others
|
|
CAP 2 (Cholesterol-amino-phosphate 2) hydrochloride is Cholesterol-amino-phosphate (CAP) lipid. CAP 2 can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
- HY-W800625
-
|
|
ADC Linker
|
Cancer
|
|
Boc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
|
-
- HY-W800623
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-PEG6-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
|
-
- HY-W800621
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine for use in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
|
-
- HY-W800624
-
|
|
ADC Linker
|
Cancer
|
|
Boc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
|
-
- HY-W800622
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
|
-
- HY-153909
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .
|
-
- HY-145663
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a agent-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety .
|
-
- HY-153908
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SMP-93566 is a kind of antibody-drug conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .
|
-
- HY-164706
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
m-PEG6-Lys-Mal-Toxophore-quinoline is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164760) .
|
-
- HY-153725
-
|
|
Liposome
|
Cancer
|
|
17:1 Lyso PC is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .
|
-
- HY-W800617
-
|
|
ADC Linker
|
Cancer
|
|
NH2-PEG1-Val-Cit-PAB-OH is a cleavable ADC linker intermediate featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
|
-
- HY-W800619
-
|
|
ADC Linker
|
Others
|
|
NH2-PEG4-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
|
-
- HY-W800618
-
|
|
ADC Linker
|
Others
|
|
NH2-PEG3-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
|
-
- HY-W800620
-
|
|
ADC Linker
|
Others
|
|
NH2-PEG6-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
|
-
- HY-167774
-
-
- HY-186186
-
-
- HY-183254
-
-
- HY-122715
-
|
|
ADC Payload
DNA/RNA Synthesis
|
Cancer
|
|
(S,S)-D211 is a stereoisomer of D211. (S,S)-D211 belongs to PBD dimer family with DNA damage activity. (S,S)-D211 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-179626
-
|
|
STING
ADC Payload
|
Cancer
|
|
STING agonist-49 (Compound 1) is a STING agonist and can be used as a payload for ADCs. STING agonist-49 can be applied in lung cancer research .
|
-
- HY-177109
-
|
|
ROR
Drug-Linker Conjugates for ADC
|
Cancer
|
|
BL20-MMAE is an antibody-drug conjugate targeting ROR1, which is formed by conjugating an anti-ROR1 antibody with the Auristatin payload MMAE (HY-15162) via a BL20 linker .
|
-
- HY-185484
-
|
BMS-936561
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
|
Cancer
|
|
MDX-1203 (BMS-936561) is an antibody-drug conjugate targeting CD70. MDX-1203 binds to CD70 and mediates the specific delivery of its conjugated cytotoxic payload to tumors. MDX-1203 delivers a DNA alkylating payload into cells. MDX-1203 can be used in research related to advanced clear cell renal cell carcinoma and relapsed/refractory B-cell non-Hodgkin lymphoma .
|
-
- HY-176972
-
|
|
ADC Payload
DNA/RNA Synthesis
|
Cancer
|
|
Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid (Compound 5) is a cytotoxic pyrrolobenzodiazepine (PBD) dimer derivative. Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid exhibits moderate DNA alkylating activity. Di(MMY-SJG)-Ph-prop-2-yne-1-sulfonic acid can be used as the payload of ADC, thereby demonstrating strong antigen-dependent cytotoxicity .
|
-
- HY-185493
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-VC-PAB-seco-CBI-PBD dimer is a highly active drug-linker conjugate. Mal-VC-PAB-seco-CBI-PBD dimer integrates the DNA-damaging effects of two distinct types of compounds: seco-cyclopropabenzindoline (seco-CBI) and pyrrolobenzodiazepine (PBD). Mal-VC-PAB-seco-CBI-PBD dimer is linked via a valine-alanine (VC) linker cleavable by cathepsin B and achieves targeted delivery relying on monoclonal antibodies. Mal-VC-PAB-seco-CBI-PBD dimer is applicable for cancer research .
|
-
- HY-186185
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Others
|
|
OSu-Val-Cit-PAB-Exa (compound D) is a cleavable linker-payload conjugate (usable for ADC synthesis). OSu-Val-Cit-PAB-Exa bears an N-terminal N-hydroxysuccinimide (OSu) ester group, and comprises Val-Cit, p-aminobenzyl alcohol (PAB) and Exatecan (HY-13631). OSu-Val-Cit-PAB-Exa serves as a payload-linker intermediate for polypeptide conjugation .
|
-
- HY-181438
-
-
- HY-160969
-
|
|
ADC Payload
|
Cancer
|
|
DUBA is a toxin compound that acts on DNA, exhibiting alkylating activity. DUBA is an ADC payload that can be coupled with monoclonal antibodies to synthesize antibody-drug conjugates (ADCs) .
|
-
- HY-186191
-
-
- HY-181679
-
|
|
ADC Linker
|
Cancer
|
|
TML-2Cl is a dichloro-modified trimethyl lock adapter for antibody-drug conjugates and payload releaser.TML-2Cl undergoes 1,6-elimination followed by rapid self-cyclization to facilitate release of the payload Exatecan after cathepsin B cleavage of the associated linker.TML-2Cl exhibits high stability when conjugated to a drug and high intrinsic hydrophobicity.TML-2Cl can be used for the research of gastric carcinoma .
|
-
- HY-183866
-
|
Maleimide-KGDEVD-doxorubicin
|
HSP
IFNAR
|
Cancer
|
|
MPD-1 (Maleimide-KGDEVD-doxorubicin) is a peptide drug conjugate (PDC). MPD-1 enhances CD8 + T cell tumor infiltration, and activates antigen-presenting cells. MPD-1 enables dual-trigger payload release, amplifies cytotoxicity via in situ feedback, and selectively delivers payload to tumor microenvironments via enhanced albumin metabolism and macropinocytosis. MPD-1 exhibits antitumor efficacy in mouse colorectal cancer models. MPD-1 can be used for the research of colorectal cancer .
|
-
- HY-P991906
-
|
CD22-4AP Antibody; CAT-02-106 Antibody
|
ADC Antibody
CD22
|
Cancer
|
|
TRPH-222 Antibody (CD22-4AP Antibody) is an anti-human CD22 antibody site-specifically modified at one site per heavy chain to express formylglycine (FG), allowing site-specific conjugation of a maytansinoid payload, a protease-insensitive spacer, and a functional group for coupling to an aldehyde on antibody FG residues. TRPH-222 Antibody can generate antibody drug conjugate (ADC) (TRPH-222) with an ADC payload and a linker. TRPH-222 Antibody can be used for the study of NHL (non-Hodgkin's lymphoma) .
|
-
- HY-P991970
-
|
|
|
Cancer
|
|
REGN3124 is a fully human antibody with binding to EGFRvIII. REGN3124 forms REGN3124-PBD via conjugation to pyrrolobenzodiazepine linker-payload SG-3249. REGN3124 can be used for the research of glioblastoma multiforme .
|
-
- HY-164954
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) composed of the ADC antibody IgG1 Human IgG1 kappa, Isotype Control (HY-P99001) and the payload McMMAF (HY-15578).
|
-
- HY-159858
-
|
|
Liposome
|
Cancer
|
|
Lipid 16 is an ionizable lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads. Lipid 16 as a potent cell type-specific ionizable lipid for the CD11bhi macrophage population without an additional targeting moiety .
|
-
- HY-175353
-
|
|
FAP
|
Cancer
|
|
TriOncoFAP-GlyPro-MMAE is a small molecule drug conjugate (SMDC) targeting fibroblast activation protein (FAP) with an IC50 of 13 pmol/L. TriOncoFAP-GlyPro-MMAE combines a FAP-targeting ligand (TriOnco), a cleavable glycine-proline linker, and a cytotoxic payload (MMAE) .
|
-
- HY-128952G
-
|
SG3249
|
Drug-Linker Conjugates for ADC
DNA Alkylator/Crosslinker
|
Cancer
|
|
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
|
-
- HY-176455
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
ADC-5 drug-linker (Compound linker-payload 5) is a drug-linker conjugate for ADC with potent anti-tumor activity. ADC-5 drug-linker can be used to synthesize NLRP3 agonist 3 (HY-176452) .
|
-
- HY-126686
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate.
|
-
- HY-132031
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-Val-Ala-PAB(C2-glucuronic acid)-DMEA-PNU-159682 is an active molecule-conjugate for ADCs, composed of a cleavable Val-Ala linker and the potent ADC cytotoxic payload PNU-159682 (HY-16700) .
|
-
- HY-176478
-
|
|
ADC Linker
|
Cancer
|
|
PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC is an ADC linker that can be combined with the TLR7/8 agonist (HY-170770) for the synthesis of a linker-payload conjugate .
|
-
- HY-101161S
-
-
- HY-171689
-
|
AZD 8205; P-Sam
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
Puxitatug samrotecan (AZD 8205) is a B7-H4-directed antibody-drug conjugate (ADC) bearing a Topoisomerase I inhibitor (TOP1i) payload. Puxitatug samrotecan improves HR +/HER2 - breast cancer .
|
-
- HY-159774
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
ADC Control human IgG1-DM1 is the ADC control, which is composed of Human IgG1 kappa, Isotype Control (HY-P99001) and the linker-payload conjugate SMCC-DM1 (HY-101070) .
|
-
- HY-164919
-
-
- HY-171124
-
|
AZD9592
|
Antibody-Drug Conjugates (ADCs)
EGFR
c-Met/HGFR
Topoisomerase
DNA/RNA Synthesis
|
Cancer
|
|
Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research .
|
-
- HY-176452
-
|
|
|
Cancer
|
|
NLRP3 agonist 3 (Compound Payload 5) is an antibody-drug conjugate (ADC). NLRP3 agonist 3 is a NLRP3 agonist that induces IL-1β secretion in primary human monocytes. NLRP3 agonist 3 can be used in cancer research .
|
-
- HY-13704
-
|
7-Ethyl-10-hydroxycamptothecin
|
Drug Metabolite
Topoisomerase
ADC Payload
Autophagy
|
Cancer
|
|
SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .
|
-
- HY-101161R
-
|
|
Reference Standards
DNA Alkylator/Crosslinker
ADC Payload
|
Cancer
|
|
SG3199 (Standard) is the analytical standard of SG3199 (HY-101161). This product is intended for research and analytical applications. SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249) .
|
-
- HY-185188
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Others
|
|
ADC Control Human IgG1-DL-01 is an antibody-drug conjugate (ADC) consisting of the ADC antibody Human IgG1 lambda1, Isotype Control (HY-P99992) and the linker-payload DL-01 formic (HY-155870A).
|
-
- HY-W591441
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Fmoc-Ala-PAB-PNP is an Alanine linked to 4-aminobenzoiate (PAB) with terminal Fmoc and PNP groups. The Fmoc group can be deprotected under basic conditions to release the free amine which can be used for further conjugations. PNP is a good leaving group when reacting with an amine-bearing payload.
|
-
- HY-168913
-
|
|
PSMA
|
Cancer
|
|
CTT2274 is a prodrug of MMAE (HY-15162). CTT2274 is composed of a prostate-specific membrane antigen (PSMA)-binding scaffold, a biphenyl motif, a pH-sensitive phosphoramidate linker, and MMAE payload. CTT2274 shows selective binding to PSMA and delivers MMAE. CTT2274 inhibits prostate cancer .
|
-
- HY-179628
-
|
|
Drug Derivative
|
Cancer
|
|
STING agonist-49-CO-C2-mal-Cys (compound 2), the derivative of STING agonist-49-CO-C2-mal (HY-179627), is the product of ADC catabolism and payload release, exhibits antitumor activity in vivo .
|
-
- HY-W591440
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Fmoc-Cit-PAB-PNP is a Citrulline linked to 4-aminobenzoiate (PAB) with terminal Fmoc and PNP groups. The Fmoc group can be deprotected under basic conditions to release the free amine which can be used for further conjugations. PNP group is a good leaving group when reacting with an amine-bearing payload.
|
-
- HY-42709
-
|
Carbobenzoxy-L-valyl-L-alanine
|
Amino Acid Derivatives
|
Cancer
|
|
Z-Val-Ala-OH is a dipeptide derivative of valine and alanine. Z-Val-Ala-OH undergoes cleavage by cathepsin B and other lysosomal proteases to enable payload release following lysosomal internalization. Z-Val-Ala-OH can be used for the research of antibody-drug conjugate (ADC) development[1] .
|
-
- HY-147917
-
|
|
ADC Payload
DNA/RNA Synthesis
|
Cancer
|
|
RNA polymerase II-IN-2 is a RNA polymerase II inhibitor with a Ki value of 74.1 nM. RNA polymerase II-IN-2 inhibits Pol II-mediated transcription and induces cytotoxicity in mammalian cells. RNA polymerase II-IN-2 serves as a payload for antibody-drug conjugates (ADC) and is applicable for cancer research .
|
-
- HY-101141R
-
|
|
Drug-Linker Conjugates for ADC
Reference Standards
|
Cancer
|
|
sulfo-SPDB-DM4 (Standard) is the analytical standard of sulfo-SPDB-DM4 (HY-101141). This product is intended for research and analytical applications. sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
|
-
- HY-147193A
-
|
|
NAMPT
|
Cancer
|
|
Nampt-IN-10 trihydrochloride (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 trihydrochloride shows cellular potency to A2780 and CORL23 cell lines with IC50 values of 5 and 19 nM, respectively. Nampt-IN-10 trihydrochloride can be used as a novel non-antimitotic payload for antibody-drug conjugate (ADC) .
|
-
- HY-179627
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
STING agonist-49-CO-C2-mal (compound ncSTING linker-payload) is a non-cleavable drug-linker conjugate for ADC. STING agonist-49-CO-C2-mal can be used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
- HY-177244
-
|
|
PROTACs
ADC Payload
Epigenetic Reader Domain
|
Cancer
|
|
EBET-1593 is a BET PROTAC degrader. EBET-1593 can promote the ubiquitination and degradation of BET. EBET-1593 is a lead payload. EBET-1593 can be used to synthesize ADCs, such as 84-EBET. 84-EBET has antitumor effects against pancreatic ductal adenocarcinoma .
|
-
- HY-179660
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
STING agonist-49-PAB-Ala-Val-CO-C2-mal, a pep-cSTING linker-payload, is a drug-linker conjugate for ADC. STING agonist-49-PAB-Ala-Val-CO-C2-mal can be used for ADC synthesis .
|
-
- HY-W076556
-
|
((Allyloxy)carbonyl)-L-valyl-L-alanine
|
Biochemical Assay Reagents
|
Others
|
|
Alloc-Val-Ala-OH (((Allyloxy)carbonyl)-L-valyl-L-alanine) is a building block in the synthesis of Tesirine, a clinical antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. The Val-Ala will specifically be cleaved by Cathepsin B. The Alloc group is stable to treatment with piperidine and TFA, but can be easily removed under mild conditions by palladium catalyzed allyl transfer.
|
-
- HY-183623
-
|
|
ADC Payload
Apoptosis
|
Cancer
|
|
ProAlk01 is a protein alkylating agent that serves as a toxin payload for ADCs. ProAlk01 localizes to the cytoplasm and exerts cytotoxic effects mainly by alkylating cytoplasmic proteins rather than binding to DNA. ProAlk01 induces cell cycle arrest, apoptosis, and immunogenic cell death. ProAlk01 can be used in the research of solid tumors .
|
-
- HY-P99813
-
|
HER3-DXd; U3-1402
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
|
-
- HY-P991899
-
|
LCB73 Antibody
|
ADC Antibody
CD19
|
Cancer
|
|
IKS03 Antibody (LCB73 Antibody) is an anti-human CD19 antibody. IKS03 Antibody can generate antibody drug conjugate (ADC) (IKS03) with a pyrrolobenzodiazepine (PBD) dimer payload. IKS03 Antibody can be used for the study of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) .
|
-
- HY-79490
-
|
|
ADC Payload
Topoisomerase
|
Cancer
|
|
Ac-Exatecan is acetylation-modified Exatecan (HY-13631). Exatecan is a common toxin component in ADC preparation (ADC cytotoxin) and an inhibitor of DNA topoisomerase I (IC50 = 2.2 μM). Exatecan has antitumor activity. Exatecan can be used as a payload for ADC. Exatecan is effective against P-glycoprotein mediated multi-drug resistant cells .
|
-
- HY-177267
-
|
|
Drug Derivative
ADC Payload
|
Cancer
|
|
Camptothecin derivative-3 (Compound 11) is a derivative of Camptothecin (HY-16560) and can serve as a payload for ADCs. Camptothecin derivative-3 has certain cytotoxicity, with IC50 values of 2 nM and 0.9 nM against HSC-2 and Namalwa/luc cells, respectively. Camptothecin derivative-3 can be used in tumor-related research .
|
-
- HY-103688
-
|
|
ADC Payload
|
Cancer
|
|
AcBut-N-Ac-γ-Calicheamicin is an ADC cytotoxic payload that induces cell cycle arrest and apoptosis by causing DNA double-strand breaks. AcBut-N-Ac-γ-Calicheamicin is primarily used in the synthesis of antibody-drug conjugates (ADC) and holds promise for research in the field of cancer, including acute lymphoblastic leukemia (ALL) and other hematological malignancies .
|
-
- HY-24144
-
|
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
Tesirine intermediate-2 is the intermediate of Tesirine (HY-128952). Tesirine (SG3249), a pyrrole benzodiazepine (PBD) dimer, is a DNA small channel crosslinker with strong cytotoxicity. Tesirine can be used to synthesize Antibody-Drug Conjugates (ADCs), the warhead component of the payload is SG3199 (HY-101161), which has strong anticancer cell activity.
|
-
- HY-160806
-
|
|
ADC Payload
Topoisomerase
|
Cancer
|
|
(5-Cl)-Exatecan is a derivative of Exatecan (HY-13631) and a DNA topoisomerase inhibitor. (5-Cl)-Exatecan serves as the cytotoxic payload component in antibody-drug conjugates (ADC) targeting ROR1-positive cancers. (5-Cl)-Exatecan is applicable for the research of ROR1-positive cancers .
|
-
- HY-145399
-
|
SG 3932; AZ-0133
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
AZ14170133 (SG 3932; AZ-0133) is a Drug-Linker Conjugates for ADC. AZ14170133 consists of the ADC cytotoxic payload topoisomerase 1 inhibitor and a linker. AZ14170133 can be used for synthesis of ADC AZD9592 (HY-171124) and AZD 8205 (HY-171689). AZ14170133 can be used for the research of cancer .
|
-
- HY-47820
-
|
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
Tesirine intermediate-1 is the intermediate of Tesirine (HY-128952). Tesirine (SG3249), a pyrrole benzodiazepine (PBD) dimer, is a DNA small channel crosslinker with strong cytotoxicity. Tesirine can be used to synthesize Antibody-Drug Conjugates (ADCs), the warhead component of the payload is SG3199 (HY-101161), which has strong anticancer cell activity.
|
-
- HY-151207
-
|
|
Apoptosis
ADC Payload
|
Cancer
|
|
Anticancer agent 81 (Compound 37b3) is an anticancer agent and can induce tumor cell cycle arrest and apoptosis. Anticancer agent 81 can be used as a payload to conjugate with Trastuzumab (HY-P9907) to obtain the antibody–agent conjugate (ADC) T-PBA. T-PBA maintained its mode of target and internalization ability of Trastuzumab .
|
-
- HY-177710
-
|
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
MEDI4276 is a biparatopic tetravalent antibody targeting two nonoverlapping epitopes in subdomains 2 and 4 of the HER2 ecto-domain. MEDI4276 is composed of MEDI4276 Antibody (HY-P991238) and a cytotoxic payload AZ1508 (HY-128962) linked through site-specific coupling. MEDI4276 exhibits antitumor activity .
|
-
- HY-164163
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT (example 4-3) is an ADC drug-linker conjugate composed of an payload 7-MAD-MDCPT (HY-132162) and a linker MP-PEG8-Val-Lys-Gly (HY-179261), used for synthesizing ADC .
|
-
- HY-400690
-
|
|
Drug Intermediate
|
Cancer
|
|
TAM558 intermediate-4 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .
|
-
- HY-W800814
-
|
|
ADC Linker
|
Cancer
|
|
Azido-PEG8-Amido-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome, the ADC payload will be released only in the cell. Azido will react with DBCO, BCN or other alkyne groups through click chemistry. PEG spacer increases aqueous solubility. Reagent grade, for research purpose.
|
-
- HY-48564
-
|
|
ADC Payload
|
Cancer
|
|
TAM558 intermediate-54 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .
|
-
- HY-144880
-
|
3-Aminophenyl Hemiasterlin
|
ADC Payload
Microtubule/Tubulin
P-glycoprotein
|
Cancer
|
|
SC209 (3-Aminophenyl Hemiasterlin) is a 3-aminophenyl hemiasterlin derivative that serves as a cytotoxin for ADCs, targeting tubulin. SC209 has reduced potential for drug efflux via P-glycoprotein 1 drug pump compared with other tubulin-targeting payloads. SC209 exhibits antitumor activity and can be used in the synthesis of ADC molecules .
|
-
- HY-400687
-
|
|
Drug Intermediate
|
Cancer
|
|
TAM558 intermediate-1 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .
|
-
- HY-400688
-
|
|
ADC Payload
|
Cancer
|
|
TAM558 intermediate-24 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .
|
-
- HY-400689
-
|
|
Drug Intermediate
|
Cancer
|
|
TAM558 intermediate-34 is an intermediate in the synthesis of TAM558 (HY-148127).TAM558 is the payload molecule used in the synthesis of OMTX705.OMTX705 is a humanized anti-fibroblast activation protein (FAP) antibody that binds to the cytolysin TAM470 (HY-148128) and has anti-tumor activity .
|
-
- HY-150233
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Cys-McMMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody conjugated to the microtubule disrupting MMAF (HY-15579) via a maleimidocaproyl linker. Cys-McMMAF has antitumor efficacy in two tumor mouse models (H1975 and MDA-MB-361-DYT2 models) .
|
-
- HY-P11101
-
|
|
Biochemical Assay Reagents
|
Others
|
|
plCSA-BP is a Placental CSA-binding peptide. plCSA-BP binds specifically to trophoblasts and not to other cell types in the placenta or to CSA-expressing cells in other tissues. plCSA-BP can guide nanoparticles for the targeted delivery of payloads (such as Indocyanine green (ICG) (HY-D0711) and Methotrexate (MTX) (HY-14519)) to the placenta, promising for placenta-specific drug delivery .
|
-
- HY-179659
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal (compound gluc-cSTING linker-payload) is a drug-linker conjugate for ADC. STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal can be used for ADC synthesis .
|
-
- HY-183912
-
|
|
Topoisomerase
ADC Payload
|
Cancer
|
|
PY-4Car2 is a Camptothecin (HY-16560) derivative and a topoisomerase I inhibitor. PY-4Car2 functions as a warhead conjugated via a cleavable linker to the bispecific ADC TJ101. PY-4Car2 can be used as an ADC payload for the research of cancers .
|
-
- HY-185488
-
|
|
DNA Alkylator/Crosslinker
ADC Payload
|
Cancer
|
|
seco-CBI dimer is a DNA alkylating agent and a prodrug of Duocarmycin, which can serve as a payload for synthesizing antibody-drug conjugates (ADCs). seco-CBI dimer binds to the minor groove of A-T-rich regions in DNA, alkylates the N3 position of adenine residues, and induces DNA strand breaks. seco-CBI dimer can be used in the research of non-Hodgkin's lymphoma .
|
-
- HY-170971
-
|
|
Apoptosis
Src
|
Cancer
|
|
Src Inhibitor 4 (Compound 18) is a derivative of KX-01 and an Src inhibitor. Src Inhibitor 4 can inhibit tumor cells, disrupt microtubules, and induce cell cycle arrest, apoptosis, and immunogenic cell death. After the introduction of phenolic or aniline functionality, Src Inhibitor 4 can serve as a payload attachment site for antibody-drug conjugates and has anti-tumor activity .
|
-
- HY-152919
-
|
|
ADC Linker
|
Cancer
|
|
Mal-amide-PEG8-Val-Cit-PAB-OH is a cleavable ADC linker featuring a maleimide, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB functional group. Maleimide is used to covalently bind free thiols on the cysteine residues of proteins. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery with the help of the PAB structure.
|
-
- HY-101982A
-
|
(Rac)-Lys-Nε-MCC-DM1
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1 (HY-101982). Lys-SMCC-DM1 is a linker-payload component that has the potential to inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1 .
|
-
- HY-175023
-
|
|
Phosphatase
|
Cancer
|
|
OncoACP3 is a small-molecule ligand of prostatic acid phosphatase (ACP3) with an IC50 of 0.30 nM. OncoACP3 has a modular structure that supports flexible payload delivery. After radiolabeling with Lu-177 it selectively accumulates in ACP3-expressing tumors with a long retention time, enabling targeted radiation delivery. OncoACP3 is applicable to research related to prostate cancer .
|
-
- HY-153795
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan is a bioactive drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC). Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan consists of Exatecan (HY-13631) and a linker. Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan is applicable to ADC synthesis and cancer research. Exatecan acts as a DNA Topoisomerase I inhibitor .
|
-
- HY-157763
-
|
|
PROTAC-Linker Conjugates for PAC
Btk
|
Cancer
|
|
Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 is a cleavable linker-payload conjugate and cereblon-binding BTK bifunctional degrader. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 induces BTK degradation and exerts cytotoxic effects when delivered via CD79b monoclonal antibody. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1, when formulated as a CD79b antibody-drug conjugate, achieves sustained in vivo BTK degradation in tumor-bearing mice with reduced systemic payload exposure. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be used for the research of activated b-cell-like diffuse large b-cell lymphoma (ADC linker: (HY-130944); PROTAC: (HY-163295)) .
|
-
- HY-129589
-
|
|
ADC Payload
|
Cancer
|
|
Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC50=650 nM). Thailanstatin A exerts effects via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome and shows low-nM to sub-nM IC50s against multiple cancer cell lines. Thailanstatin A, a payload for ADCs, is conjugated to the lysines on trastuzumab yielding “linker-less” ADC .
|
-
- HY-164340
-
|
|
Drug Metabolite
|
Cancer
|
|
Boc-NH-PAB(triacetyl-β-D-glucopyranuronate)-PNP (Compound 16) is a β-glucuronide-type linker precursor that couples with NeoDegrader P1 to synthesize the NeoDegrader P1-β-Glucuronide Linker Complex. Boc-NH-PAB(triacetyl-β-D-glucopyranuronate)-PNP and its derived linker-payload complexes can be used for the research of acute myeloid leukemia .
|
-
- HY-148424
-
|
|
ADC Payload
DNA Alkylator/Crosslinker
|
Cancer
|
|
PBD dimer-2 (compound 2c) is a C8-linked pyrrolobenzodiazepine dimer. PBD dimer-2 can span an extra base pair and cross-link the 5′-Pu-GA(T/A)TC-Py sequence. PBD dimer-2 can be used as a payload for antibody–agent conjugates (ADCs), and it can be used for the research of cancer .
|
-
- HY-13704R
-
|
7-Ethyl-10-hydroxycamptothecin (Standard)
|
Drug Metabolite
Reference Standards
Topoisomerase
ADC Payload
Autophagy
|
Cancer
|
|
SN-38 (Standard) is the analytical standard of SN-38. This product is intended for research and analytical applications. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .
|
-
- HY-112616
-
|
|
NAMPT
Drug-Linker Conjugates for ADC
|
Cancer
|
|
NAMPT inhibitor-linker 2 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC50s of <7 pM and 40 pM, respectively.
|
-
- HY-175023A
-
|
|
Phosphatase
|
Cancer
|
|
OncoACP3 TFA is a small-molecule ligand of prostatic acid phosphatase (ACP3) with an IC50 of 0.30 nM. OncoACP3 TFA has a modular structure that supports flexible payload delivery. After radiolabeling with Lu-177 it selectively accumulates in ACP3-expressing tumors with a long retention time, enabling targeted radiation delivery. OncoACP3 TFA is applicable to research related to prostate cancer .
|
-
- HY-164789
-
|
SKB264; MK-2870
|
Antibody-Drug Conjugates (ADCs)
TROP2
|
Cancer
|
|
Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC50 of 2.787 ng/ml, TROP2 Ka of 0.3083 nM, and topoisomerase I IC50 of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .
|
-
- HY-112615
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
NAMPT inhibitor-linker 1 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC50s of <3 pM and 9 pM, respectively.
|
-
- HY-182719
-
|
|
Arginase
|
Cancer
|
|
AZD0011, a prodrug of AZD0011-PL (HY-182718), is an orally active arginase 1 inhibitor with an IC50 of 328 nM. AZD0011 undergoes in vivo hydrolysis to release an arginase inhibitor payload, inhibiting arginine hydrolysis, increases arginine levels in plasma and the tumor microenvironment. AZD0011 restores innate immune function and inhibits tumor growth. AZD0011 can be used for the research of cancer, such as fibrosarcoma .
|
-
- HY-181833
-
|
|
ADC Payload
PI3K
|
Cancer
|
|
PI3K/PIKK-IN-1 is a PI3K and PIKK inhibitor that serves as a payload for antibody-drug conjugates (ADC) to prepare ADC. PI3K/PIKK-IN-1 is applicable to research related to breast cancer, multiple myeloma, Burkitt lymphoma, diffuse large B-cell lymphoma, and non-small cell lung cancer .
|
-
- HY-171718
-
|
|
DNA Alkylator/Crosslinker
ADC Payload
|
Cancer
|
|
seco-CBI-PBD dimer is a CBI-PBD heterodimer and a minor groove DNA crosslinker. seco-CBI-PBD dimer exhibits cytotoxicity against human tumor cells at sub-pM to low nM levels, shows low sensitivity to P-glycoprotein-mediated drug resistance, and can serve as an ADC payload. seco-CBI-PBD dimer can be used in studies of uterine cancer, breast cancer, non-small cell lung cancer, etc.
|
-
- HY-164763
-
|
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
SHR-A1201 is a HER2-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer .
|
-
- HY-171191
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
c-Met/HGFR
|
Cancer
|
|
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528) .
|
-
- HY-164762
-
|
SHR-A1811
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .
|
-
- HY-130161
-
|
|
ADC Linker
PROTAC Linkers
|
Cancer
|
|
m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab (HY-P9907). m-PEG4-Br is placed distally from the monomethyl auristatin E (MMAE) payload to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency . m-PEG4-Br also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-173070
-
|
|
Toll-like Receptor (TLR)
IFNAR
PD-1/PD-L1
ADC Payload
|
Inflammation/Immunology
Cancer
|
|
TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC50 of 5.2 nM for human TLR7 (EC50 for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .
|
-
- HY-145636
-
|
AEX4089DC1; MGC018
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity .
|
-
- HY-185279
-
|
HS-20093; GSK5764227
|
Antibody-Drug Conjugates (ADCs)
CD276/B7-H3
|
Cancer
|
|
Risvutatug rezetecan (HS-20093; GSK5764227) is a B7-H3-targeting antibody-drug conjugate (ADC). Risvutatug rezetecan binds to B7-H3 on tumor cells and delivers a topoisomerase I inhibitor payload via a tumor microenvironment-responsive cleavable linker. Risvutatug rezetecan is applicable for the research of extensive-stage small cell lung cancer and non-small cell lung cancer .
|
-
- HY-185427
-
|
IMGN-151
|
Antibody-Drug Conjugates (ADCs)
Folate Receptor (FR)
|
Cancer
|
|
Opugotamig olatansine (IMGN151) is a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC). Opugotamig olatansine comprises antibody Opugotamig (HY-P990935) and linker-payload NMS-P945 (HY-185569). Opugotamig olatansine binds to two independent epitopes of FRα and promotes antibody binding, internalization, and processing. Opugotamig olatansine can be used for the research of FRα-positive ovarian cancer .
|
-
- HY-181911
-
|
|
Drug-Linker Conjugates for ADC
NAMPT
|
Neurological Disease
|
|
L2-FK866 is an ADC payload-linker conjugate (Drug-linker conjugate for ADC). L2-FK866 contains the ADC linker (Val-Cit-p-aminobenzyl) and the NAMPT inhibitor FK866 (HY-50876). L2-FK866 can be conjugated with Dinutuximab (HY-P9933) to form an ADC. L2-FK866 is applicable to neuroblastoma research .
|
-
- HY-160756
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
Val-Cit-Exatecan is a peptide-linked anti-tumor payload that can be used for the synthesis of antibody-drug conjugates (ADC). Val-Cit-Exatecan consists of DNA TopI inhibitor Exatecan (HY-13631) and a cathepsin-cleavable ADC linker (valine-citrulline). Val-Cit-Exatecan can be used in the research of colorectal cancer, gastric cancer, breast cancer, non-small cell lung cancer, ovarian cancer, head and neck cancer, pancreatic cancer, cervical cancer, and melanoma .
|
-
- HY-186088
-
|
|
Drug Intermediate
|
Others
|
|
DOTA-tris (t-Bu) ester-PEG3-C2-amine (Compound 9) is a conjugate of DOTA-based chelator and linker, bearing tris (t-Bu) ester and PEG3-C2-amine functional groups. DOTA-tris (t-Bu) ester-PEG3-C2-amine can be conjugated to payloads via bioorthogonal click chemistry for targeted delivery .
|
-
- HY-164734
-
|
R-DXd; DS-6000
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Raludotatug Deruxtecan is an antibody-drug conjugate targeting CDH6, with an EC50 of 64.7 ng/mL in humans, 70.4 ng/mL in cynomolgus monkeys, and 228 ng/mL in mice. Raludotatug Deruxtecan specifically binds to CDH6 on the surface of cancer cells, triggers lysosomal internalization, and releases the DXd payload that inhibits TOP1. Raludotatug Deruxtecan induces DNA damage, Chk1 phosphorylation, caspase-3 cleavage, apoptosis, and bystander cell death. Raludotatug Deruxtecan is applicable to research related to serous ovarian cancer and renal cell carcinoma .
|
-
- HY-176415
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Cys-MC-GGFG-Dxd is a cysteine-modified, cleavable ADC drug-linker conjugate. Cys-MC-GGFG-Dxd consists of a maleimidocaproyl-glycine-glycine-L-phenylalanine-glycine (MC-GGFG) linker and an Exatecan (HY-13631) derivative (DXd) (HY-13631D) payload. Cys-MC-GGFG-Dxd can be further conjugated to anti-HER2 IgG1κ antibody for the synthesis of antibody-drug conjugates (ADC), such as the breast cancer-targeting ADC compound Fam-trastuzumab deruxtecan-nxki (Enhertu) .
|
-
- HY-126690
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate . DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-164346
-
|
|
Microtubule/Tubulin
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Amine-PEG8-Val-Cit-PAB-MMAE is a potent drug-linker conjugate for antibody-drug conjugates (ADCs).Amine-PEG8-Val-Cit-PAB-MMAE consists of the linker amine-PEG8-Vali-Cit-PAB and the payload MMAE (HY-15162), and can be used to synthesize ADCs. Amine-PEG8-Val-Cit-PAB-MMAE can be used for the research of gastric cancer, colon cancer, lung adenocarcinoma .
|
-
- HY-P99829
-
|
PF-06647020; ABBV-647; h6M24-vc0101
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .
|
-
- HY-175615
-
|
|
ADC Payload
Glutathione Peroxidase
Ferroptosis
|
Cancer
|
|
RSL3-NH2 is a GPX4 inhibitor and ferroptosis inducer. RSL3-NH2 triggers the iron-dependent cell death pathway associated with lipid peroxidation by inhibiting GPX4 activity. RSL3-NH2 exhibits significant cytotoxicity against colorectal cancer cells and effectively induces their ferroptosis. RSL3-NH2 can serve as a ADC payload for synthesizing antibody-drug conjugates (ADC) and be used in colorectal cancer-related research .
|
-
- HY-185101
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-AcLys-GDEVD-PABC-Exatecan (MC-AcLys-GDEVD-PABC-DX8951) is a agent-linker conjugate for ADC. MC-AcLys-GDEVD-PABC-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with a novel caspase-3 cleavable peptide linker MC-AcLys-GDEVD-PABC linker. MC-AcLys-GDEVD-PABC-Exatecan can be used to prepare DX8951 antibody conjugate (ADC), and it exhibites significant bystander effect mediated by the caspase-3-triggered extracellular cleavage of the linker, enhancing payload release into the tumor microenvironment.
|
-
- HY-P991294
-
|
|
ADC Antibody
|
Cancer
|
|
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
|
-
- HY-185460
-
|
|
Antibody-Drug Conjugates (ADCs)
EGFR
PI3K
mTOR
|
Cancer
|
|
Pertuzumab-LD3 is a humanized antibody-drug conjugate (ADC) targeting HER2. Pertuzumab-LD3 consists of the anti-HER2 humanized IgG1 monoclonal antibody Pertuzumab (HY-P9912), the cleavable linker Gly-Gly-Phe-Gly (HY-P3669), and the PI3K/mTOR-IN-21 (HY-185456) payload. Pertuzumab-LD3 can be used in research on metastatic HER2-positive breast cancer.
|
-
- HY-114256
-
|
|
PSMA
|
Cancer
|
|
EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to PSMA-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies .
|
-
- HY-P9994
-
|
SBT6050
|
Antibody-Drug Conjugates (ADCs)
EGFR
Toll-like Receptor (TLR)
|
Inflammation/Immunology
Cancer
|
|
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .
|
-
- HY-185426
-
|
SC-011
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
ABBV-011 (SC-011) is a SEZ6-targeted, antibody-drug conjugate (ADC). ABBV-011 binds cell surface-expressed SEZ6 by anti-SEZ6 antibody Turmetabart (HY-P991041), triggers ADC-receptor complex internalization into lysosomes, releases Calicheamicin (HY-19609) payload, and mediates cytotoxicity. ABBV-011 induces tumor regression and mediates selective killing of SEZ6-positive cells. ABBV-011 can be used for the research of small cell lung cancer .
|
-
- HY-178836
-
|
|
Drug-Linker Conjugates for ADC
Ras
|
Cancer
|
|
Z56-L23 is a conjugate of RAS-targeting ADC cytotoxic payload-linker with anti-tumor activity. Z56-L23 can be conjugated with HER3 antibody, EGFR antibody or EGFRxHER3 bispecific antibody to form intact antibody-drug conjugates (ADCs). ADC molecules related to Z56-L23 effectively inhibit the proliferation of tumor cells and also significantly suppress tumor growth in xenograft mouse models. Z56-L23 can be used in the research of pancreatic cancer .
|
-
- HY-138632
-
|
|
PROTACs
Epigenetic Reader Domain
PROTAC-Linker Conjugates for PAC
|
Cancer
|
|
PROTAC BRD4 Degrader linker conjugate is a linker-payload conjugate as well as a bifunctional degrader of BRD4 that binds to VHL, consisting of PROTAC and a linker. PROTAC BRD4 Degrader linker conjugate can be conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein, with DC50 values of 0.86 nM and 7.6 nM, respectively. PROTAC BRD4 Degrader linker conjugate can be used in research related to prostate cancer and acute myeloid leukemia (BRD4 ligand: (HY-129939); VHL ligand: (HY-125845)) .\n
|
-
- HY-170554
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
DNA/RNA Synthesis
|
Inflammation/Immunology
Cancer
|
|
ABBV-706 is a SEZ6-targeted topoisomerase 1 inhibitor Antibody-Drug Conjugates (ADCs), which is composed of the Linker-Payload conjugation (HY-148820) and the Anti-SEZ6 Antibody (SC17) (HY-P991041). ABBV-706 can inhibit cancer cells proliferation and induce DNA damage and G2/M arrest. ABBV-706 exhibits high efficacy against small cell lung cancer (SCLC), neuroendocrine tumors (NENs) and central nervous system (CNS) tumors .
|
-
- HY-P5098
-
|
|
Integrin
|
Neurological Disease
Cancer
|
|
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .
|
-
- HY-P990673
-
|
DSTP-3086S Antibody; RG-7450 Antibody
|
ADC Antibody
Transmembrane Glycoprotein
Mitosis
|
Cancer
|
|
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-181741
-
|
|
Cathepsin
|
Inflammation/Immunology
|
|
PI3K-001 is a cathepsin B-responsive prodrug and antifibrotic agent. PI3K-001 undergoes cathepsin B-mediated cleavage of the Val-Ala linker in fibrotic lung lesions to release an active PI3K inhibitor payload, while it remains stable in healthy tissues. PI3K-001 improves collagen deposition, tissue collapse and alveolar injury in fibrotic lung tissues. PI3K-001 is applicable for the research of pulmonary fibrosis .
|
-
- HY-P992356
-
|
|
Topoisomerase
|
Cancer
|
|
GENA-104A16 is a humanized monoclonal antibody targeting CNTN4, with multiple functions including immunostimulation, cytotoxicity and immunoregulation. By binding to CNTN4, GENA-104A16 blocks its interaction with APP, thereby restoring T cell function, inducing tumor cell death and regulating tumor-infiltrating immune cell populations. GENA-104A16 also exerts topoisomerase I inhibitory activity via the payload Exatecan (HY-13631). GENA-104A16 can be used in research related to colon cancer liver metastasis and other CNTN4-expressing solid tumors .
|
-
- HY-180557
-
|
|
Folate Receptor (FR)
|
Cancer
|
|
4A-BFA-11 is a folate-targeted PEG-MMAE conjugate that exhibits specific binding affinity for the folate receptor α (FR-α) (KD = 106.7 nM). 4A-BFA-11 achieves tumor enrichment by combining PEG-mediated long circulation (EPR effect) and folate receptor targeting. 4A-BFA-11 undergoes enzymatic cleavage at the tumor site to release the active payload, enabling precise action. 4A-BFA-11 sefficiently carries, targets, and controls the release of MMAE in tumor tissues in a HeLa mouse model. 4A-BFA-11 can be used for cervical cancer, ovarian cancer, and lung cancer research .
|
-
- HY-183253
-
|
|
Drug-Linker Conjugates for ADC
Eukaryotic Initiation Factor (eIF)
EGFR
|
Cancer
|
|
DL149 is a component of an antibody-drug conjugate (ADC) formed by conjugating the eIF4A inhibitor FD236 (HY-186186) with an ADC linker, and exhibits potential antitumor activity. DL149 can bind to an anti-HER2 antibody to form a complete ADC molecule, which precisely binds to the HER2 receptor on the surface of tumor cells. After internalization into cells, it releases the eIF4A inhibitor payload. DL149 irreversibly blocks the mRNA translation process in tumor cells, thereby inhibiting tumor cell proliferation and inducing their death. DL149 exhibits in vivo antitumor activity in the SK-OV-3 xenograft tumor model, and can be used for the research of HER2-positive solid tumors .
|
-
- HY-183594
-
|
|
Drug-Linker Conjugates for ADC
|
Others
|
|
Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal is a linker-payload conjugate. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal contains the linker D-2,4-DHB-NH2-AA(bPEG8)-Mal (HY-183595) and the cytotoxic agent Exatecan (HY-13631), a potent DNA topoisomerase I inhibitor. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal can be utilized for the development of antibody-drug conjugates (ADCs) .
|
-
- HY-12455
-
|
|
ADC Payload
Antibiotic
DNA Alkylator/Crosslinker
Apoptosis
Caspase
|
Cancer
|
|
Duocarmycin A is an antitumor antibiotic and DNA alkylating agent with broad-spectrum antibacterial activity, which can serve as a payload for synthesizing antibody-drug conjugates (ADCs). Duocarmycin A selectively binds to the AT-rich minor groove of DNA, forms covalent adducts by alkylating the adenine N3 residue, thereby disrupting DNA structure and inhibiting its replication and transcription. Duocarmycin A induces apoptosis, sub-G1 phase accumulation and chromatin condensation, reduces the levels of pro-caspase-3/9, and induces p53-independent p21 expression. Duocarmycin A is widely used in the research of various malignancies, including leukemia, sarcoma, glioblastoma, as well as multiple solid tumor models such as lung cancer, breast cancer, and colorectal cancer .
|
-
- HY-177542
-
|
Emi-Le; XMT-1660
|
|
Cancer
|
|
Emiltatug ledadotin (Emi-Le; XMT-1660) is a B7-H4-targeted antibody-drug conjugate (ADC). Emiltatug ledadotin consists of the tumor-specific anti-B7-H4 monoclonal antibody Emiltatug (HY-P990918) and the linker-payload system Ledadotin (HY-177541), with site-specific conjugation achieved via GlycoConnect click chemistry. Emiltatug ledadotin inhibits the growth of B7-H4-positive cancer cells. Emiltatug ledadotin can be used to study advanced solid tumors with B7-H4 overexpression, particularly breast cancer, ovarian cancer, and endometrial cancer .
|
-
- HY-153360
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
|
-
- HY-141860
-
|
|
PSMA
Microtubule/Tubulin
Reactive Oxygen Species (ROS)
Cytochrome P450
|
Cancer
|
|
PSMA-Val-Cit-PAB-MMAE is a small-molecule conjugate targeting PSMA, with Monomethyl auristatin E (MMAE) (HY-15162) as its cytotoxic payload. PSMA-Val-Cit-PAB-MMAE binds to PSMA, thereby being delivered into PSMA-expressing prostate cancer cells. Subsequently, the Val-Cit linker is cleaved under the mediation of cathepsin B, releasing active MMAE. PSMA-Val-Cit-PAB-MMAE inhibits CYP3A4 activity (IC50 = 11.2 μM), induces intracellular ROS production and oxidative stress, disrupts the cytoskeleton through microtubule destabilization, and induces prostate cancer cell death. PSMA-Val-Cit-PAB-MMAE can be used in research related to prostate cancer .
|
-
- HY-171509
-
|
|
Drug-Linker Conjugates for ADC
Apoptosis
|
Cancer
|
|
Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27), an agent-linker conjugate for ADC, consists the ADC linker Mal-N(Me)-C6-N(Me) and a potent ADC cytotoxin PNU-159682. Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27) selectively delivers the payload to CD46-expressing cells, where the linker is cleaved by cathepsin B to release PNU-159682, inducing DNA damage and apoptosis. Mal-N(Me)-C6-N(Me)-PNU-159682 shows durable tumor regression in xenograft (PDX) models of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) .
|
-
- HY-178219
-
|
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE contains a linker and bioactive small molecule toxins MMAE (HY-15162). Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE can conjugate with NN2101 (HY-P991293) (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) .
|
-
- HY-178275
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol (Example 9) is a conjugate of the ADC toxic molecule and the linker, where the toxic molecule part is Hydrotecan (HY-164378), and the linker part is Mc-Glu(D-Glucamine)-val-ala (HY-178309) .
|
-
- HY-177434
-
|
Precem-TcT; M 9140
|
Antibody-Drug Conjugates (ADCs)
Transmembrane Glycoprotein
Topoisomerase
|
Cancer
|
|
Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .
|
-
- HY-185397
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
2-MSP(4-OMe)-5-HA-PEG8-VA-Exatecan is a Drug-linker conjugates for ADC consisting of the ADC Cytotoxin Exatecan (HY-13631) and a linker. 2-MSP(4-OMe)-5-HA-PEG8-VA-Exatecan can be used for synthesis of ADCs .
|
-
- HY-164992
-
|
MRG002; Trastuzumab MMAE
|
Antibody-Drug Conjugates (ADCs)
EGFR
Microtubule/Tubulin
|
Cancer
|
|
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
|
-
- HY-163099
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
Apoptosis
|
Cancer
|
|
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .
|
-
- HY-177442
-
|
DS-3939
|
Antibody-Drug Conjugates (ADCs)
Mucin
Topoisomerase
Apoptosis
|
Cancer
|
|
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
|
-
- HY-177578
-
|
|
Antibody-Drug Conjugates (ADCs)
c-Kit
Apoptosis
Microtubule/Tubulin
ERK
Akt
Caspase
|
Cancer
|
|
NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research [1][2].
|
-
- HY-164729
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
Apoptosis
|
Cancer
|
|
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .
|
-
-
-
HY-L023
-
|
|
115 compounds
|
|
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.
The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 115 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.
|
| Cat. No. |
Product Name |
Type |
-
- HY-164789
-
|
SKB264; MK-2870
|
Fluorescent Dye
|
|
Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC50 of 2.787 ng/ml, TROP2 Ka of 0.3083 nM, and topoisomerase I IC50 of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .
|
-
- HY-164992
-
|
MRG002; Trastuzumab MMAE
|
Fluorescent Dye
|
|
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
|
-
- HY-177434
-
|
Precem-TcT; M 9140
|
Fluorescent Dye
|
|
Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .
|
-
- HY-170554
-
|
|
Fluorescent Dye
|
|
ABBV-706 is a SEZ6-targeted topoisomerase 1 inhibitor Antibody-Drug Conjugates (ADCs), which is composed of the Linker-Payload conjugation (HY-148820) and the Anti-SEZ6 Antibody (SC17) (HY-P991041). ABBV-706 can inhibit cancer cells proliferation and induce DNA damage and G2/M arrest. ABBV-706 exhibits high efficacy against small cell lung cancer (SCLC), neuroendocrine tumors (NENs) and central nervous system (CNS) tumors .
|
-
- HY-177442
-
|
DS-3939
|
Fluorescent Dye
|
|
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers .
|
-
- HY-164919
-
|
XMT-2056
|
Fluorescent Dye
|
|
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate targeting HER2, with an effective payload connected via a linker (LP, HY-148067) to a STING agonist (STING agonist-20, HY-148068), and has potential immune activation and anticancer activity .
|
-
- HY-164729
-
|
|
Fluorescent Dye
|
|
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .
|
-
- HY-164762
-
|
SHR-A1811
|
Fluorescent Dye
|
|
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .
|
-
- HY-107502
-
|
|
Fluorescent Dye
|
|
Cryptophycin analog 1 is an ADC payload. Cryptophycin analog 1 shows anticancer activity. Cryptophycin analog 1 displays cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1 .
|
-
- HY-P9994
-
|
SBT6050
|
Fluorescent Dye
|
|
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .
|
-
- HY-128952G
-
|
SG3249
|
Fluorescent Dye
|
|
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
|
-
- HY-171191
-
|
|
Fluorescent Dye
|
|
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528) .
|
| Cat. No. |
Product Name |
Type |
-
- HY-46759
-
|
|
Biochemical Assay Reagents
|
|
Genevant CL1 is an ionizable lipid (pKa = 6.3) suitable for the preparation of lipid nanoparticles (LNPs) for delivering nucleic acid payloads and intramuscular vaccines. Genevant CL1 is a component of lipid nanoparticle delivery systems for mRNA vaccines .
|
-
- HY-46759A
-
|
|
Biochemical Assay Reagents
|
|
Genevant CL1 monohydrochloride is an ionizable lipid (pKa = 6.3) suitable for the preparation of lipid nanoparticles (LNPs) for delivering nucleic acid payloads and intramuscular vaccines. Genevant CL1 monohydrochloride is a component of lipid nanoparticle delivery systems for mRNA vaccines .
|
-
- HY-128952G
-
|
SG3249
|
Biochemical Assay Reagents
|
|
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10736A
-
|
|
GCGR
|
Metabolic Disease
|
|
AMG133 peptide payload TFA is a GLP-1 analog agonist peptide. AMG133 peptide payload TFA potently activates GLP-1R and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload TFA can be used for the synthesis of AMG 133 (HY-164535) .
|
-
- HY-P10736
-
|
|
GCGR
|
Metabolic Disease
|
|
AMG133 peptide payload is a GLP-1 analog agonist peptide. AMG133 peptide potently activates GLP-1R, and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload can be used for the synthesis of AMG 133 (HY-164535) .
|
-
- HY-P5098
-
|
|
Integrin
|
Neurological Disease
Cancer
|
|
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .
|
-
- HY-42709
-
|
Carbobenzoxy-L-valyl-L-alanine
|
Amino Acid Derivatives
|
Cancer
|
|
Z-Val-Ala-OH is a dipeptide derivative of valine and alanine. Z-Val-Ala-OH undergoes cleavage by cathepsin B and other lysosomal proteases to enable payload release following lysosomal internalization. Z-Val-Ala-OH can be used for the research of antibody-drug conjugate (ADC) development[1] .
|
-
- HY-P11101
-
|
|
Biochemical Assay Reagents
|
Others
|
|
plCSA-BP is a Placental CSA-binding peptide. plCSA-BP binds specifically to trophoblasts and not to other cell types in the placenta or to CSA-expressing cells in other tissues. plCSA-BP can guide nanoparticles for the targeted delivery of payloads (such as Indocyanine green (ICG) (HY-D0711) and Methotrexate (MTX) (HY-14519)) to the placenta, promising for placenta-specific drug delivery .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P990673
-
|
DSTP-3086S Antibody; RG-7450 Antibody
|
ADC Antibody
Transmembrane Glycoprotein
Mitosis
|
Cancer
|
|
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC) .
|
-
(5)
-
- HY-P99829
-
|
PF-06647020; ABBV-647; h6M24-vc0101
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .
|
-
(5)
-
- HY-141600
-
|
BAY 1187982
|
Antibody-Drug Conjugates (ADCs)
FGFR
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .
|
-
(5)
-
- HY-P9994
-
|
SBT6050
|
Antibody-Drug Conjugates (ADCs)
EGFR
Toll-like Receptor (TLR)
|
Inflammation/Immunology
Cancer
|
|
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .
|
-
(5)
-
- HY-P991294
-
|
|
ADC Antibody
|
Cancer
|
|
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
|
-
(5)
-
- HY-P991906
-
|
CD22-4AP Antibody; CAT-02-106 Antibody
|
ADC Antibody
CD22
|
Cancer
|
|
TRPH-222 Antibody (CD22-4AP Antibody) is an anti-human CD22 antibody site-specifically modified at one site per heavy chain to express formylglycine (FG), allowing site-specific conjugation of a maytansinoid payload, a protease-insensitive spacer, and a functional group for coupling to an aldehyde on antibody FG residues. TRPH-222 Antibody can generate antibody drug conjugate (ADC) (TRPH-222) with an ADC payload and a linker. TRPH-222 Antibody can be used for the study of NHL (non-Hodgkin's lymphoma) .
|
-
(5)
-
- HY-P991970
-
|
|
|
Cancer
|
|
REGN3124 is a fully human antibody with binding to EGFRvIII. REGN3124 forms REGN3124-PBD via conjugation to pyrrolobenzodiazepine linker-payload SG-3249. REGN3124 can be used for the research of glioblastoma multiforme .
|
-
(5)
-
- HY-P991899
-
|
LCB73 Antibody
|
ADC Antibody
CD19
|
Cancer
|
|
IKS03 Antibody (LCB73 Antibody) is an anti-human CD19 antibody. IKS03 Antibody can generate antibody drug conjugate (ADC) (IKS03) with a pyrrolobenzodiazepine (PBD) dimer payload. IKS03 Antibody can be used for the study of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) .
|
-
(5)
-
- HY-P992356
-
|
|
Topoisomerase
|
Cancer
|
|
GENA-104A16 is a humanized monoclonal antibody targeting CNTN4, with multiple functions including immunostimulation, cytotoxicity and immunoregulation. By binding to CNTN4, GENA-104A16 blocks its interaction with APP, thereby restoring T cell function, inducing tumor cell death and regulating tumor-infiltrating immune cell populations. GENA-104A16 also exerts topoisomerase I inhibitory activity via the payload Exatecan (HY-13631). GENA-104A16 can be used in research related to colon cancer liver metastasis and other CNTN4-expressing solid tumors .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-156756S
-
|
|
|
7-Hydroxymethyl-10,11-MDCPT-d5 is deuterium labeled 7-Hydroxymethyl-10,11-MDCPT, which is a is a payload that can be used for ADC synthesis .
|
-
-
- HY-101161S
-
|
|
|
SG3199-d6 is the deuterium labeled SG3199 (HY-101161). SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249).
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-147363
-
|
|
|
ADC Synthesis
DBCO
|
|
DIBAC-GGFG-NH2CH2-Dxd (compound LP4), a Camptothecin (HY-16560) derivative, is a linker-payload of protein-agent conjugates . Dxd (HY-13631D) can be used as a payload for the antibody-coupling drug ADC (DS-8201a).DIBAC-GGFG-NH2CH2-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .
|
-
- HY-126690
-
|
|
|
DBCO
|
|
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate . DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-163099
-
|
|
|
Alkynes
|
|
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .
|
-
- HY-W190913
-
|
|
|
DBCO
|
|
DBCO-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. PNP can be substituted by amine-containing payload. DBCO enable click chemistry with azide molecules.
|
-
- HY-W800814
-
|
|
|
Azide
|
|
Azido-PEG8-Amido-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome, the ADC payload will be released only in the cell. Azido will react with DBCO, BCN or other alkyne groups through click chemistry. PEG spacer increases aqueous solubility. Reagent grade, for research purpose.
|
-
- HY-181679
-
|
|
|
Azide
|
|
TML-2Cl is a dichloro-modified trimethyl lock adapter for antibody-drug conjugates and payload releaser.TML-2Cl undergoes 1,6-elimination followed by rapid self-cyclization to facilitate release of the payload Exatecan after cathepsin B cleavage of the associated linker.TML-2Cl exhibits high stability when conjugated to a drug and high intrinsic hydrophobicity.TML-2Cl can be used for the research of gastric carcinoma .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-46759
-
|
|
|
Cationic Lipids
|
|
Genevant CL1 is an ionizable lipid (pKa = 6.3) suitable for the preparation of lipid nanoparticles (LNPs) for delivering nucleic acid payloads and intramuscular vaccines. Genevant CL1 is a component of lipid nanoparticle delivery systems for mRNA vaccines .
|
-
- HY-159858
-
|
|
|
Cationic Lipids
|
|
Lipid 16 is an ionizable lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads. Lipid 16 as a potent cell type-specific ionizable lipid for the CD11bhi macrophage population without an additional targeting moiety .
|
-
- HY-159865
-
|
|
|
Cationic Lipids
|
|
CL15F6 is an ionizable lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
- HY-159856
-
|
Diphosphatidylglycerol (16:0)
|
|
Phospholipids
|
|
16:0 Cardiolipin (Diphosphatidylglycerol (16:0)) is a phospholipid derived from Palmitic acid (16:0) that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
- HY-159862
-
|
|
|
Cationic Lipids
|
|
IM21.7c is a cationic lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
- HY-W591449
-
|
|
|
Pegylated Lipids
|
|
DOPE-PEG2000-Azide is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .
|
-
- HY-46759A
-
|
|
|
Cationic Lipids
|
|
Genevant CL1 monohydrochloride is an ionizable lipid (pKa = 6.3) suitable for the preparation of lipid nanoparticles (LNPs) for delivering nucleic acid payloads and intramuscular vaccines. Genevant CL1 monohydrochloride is a component of lipid nanoparticle delivery systems for mRNA vaccines .
|
-
- HY-177571
-
|
Sgc8c-VcMMAE
|
|
Aptamers
|
|
Sgc8c-M is a PTK7-targeted aptamer-drug conjugate (ApDC). Sgc8c-M is composed of the classic PTK7-specific aptamer Sgc8c, a cathepsin B (CTSB)-cleavable valine-citrulline (VC)-based linker, and the potent antimitotic agent Monomethyl auristatin E (MMAE) (HY-15162) as the payload. Sgc8c-M inhibits the growth of PTK7-overexpressing cancer cells. Sgc8c-M can be used for the study of PTK7-expressing advanced solid tumors .
|
-
- HY-160512
-
|
|
|
Cationic Lipids
|
Lipid 9 is an ionizable lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
- HY-159853
-
|
|
|
Cationic Lipids
|
|
C14-A1 is an ionizable cationic lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
-
- HY-159855
-
|
Cholesterol-amino-phosphate 2 hydrochloride
|
|
Cholesterol
|
|
CAP 2 (Cholesterol-amino-phosphate 2) hydrochloride is Cholesterol-amino-phosphate (CAP) lipid. CAP 2 can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads .
|
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-128952G
-
|
SG3249
|
Drug-Linker Conjugates for ADC
DNA Alkylator/Crosslinker
|
Cancer
|
|
Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![Exatecan-amide-bicyclo[1.1.1]pentan-1-ol](http://file.medchemexpress.com/product_pic/hy-160597.gif)
